Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients

BACKGROUND: KRAS mutation is a negative predictive factor for treatment with anti-epidermal growth factor receptor (EGFR) antibodies in metastatic colorectal cancer (mCRC). Novel predictive markers are required to further improve the selection of patients for this treatment. We assessed the influenc...

Descripción completa

Detalles Bibliográficos
Autores principales: Mekenkamp, Leonie JM, Tol, Jolien, Dijkstra, Jeroen R, de Krijger, Inge, Vink-Börger, M Elisa, van Vliet, Shannon, Teerenstra, Steven, Kamping, Eveline, Verwiel, Eugène, Koopman, Miriam, Meijer, Gerrit A, van Krieken, J Han JM, Kuiper, Roland, Punt, Cornelis JA, Nagtegaal, Iris D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508829/
https://www.ncbi.nlm.nih.gov/pubmed/22804917
http://dx.doi.org/10.1186/1471-2407-12-292

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508829/
https://www.ncbi.nlm.nih.gov/pubmed/22804917
http://dx.doi.org/10.1186/1471-2407-12-292

Ejemplares similares